Our score, based on the PEGASUS-TIMI 54 criteria, may identify AMI patients at high risk of recurrent ischemic events, who might benefit from thorough preventive strategies.Īcute myocardial infarction PEGASUS-TIMI 54 Prognosis Risk score.Ĭopyright © 2018 Elsevier B.V. The prognostic performance of the score cut-off persisted beyond the first year after AMI in the validation cohort, maintaining a similar risk for death and non-fatal AMI (HR 3) at every following year. One-year major bleeding rate was low (<0.2% overall) and similar between risk groups. At multivariate analysis, the HR for the primary endpoint associated with a score ≥ 6 was 4.45 (P < 0.0001) in the derivation cohort and 2.86 (P < 0.0001) in the validation cohort. January 14, 2015AstraZeneca announced that the PEGASUS-TIMI 54 study met its primary efficacy endpoint. The marketing authorisation for ticagrelor as an extended therapy was based on prespecified subgroup analyses.
Pegasus timi 54 trial#
The primary endpoint incidence in patients with a score above and below the cut-off was 12% and 3% (P < 0.001) in the derivation cohort and 16% and 6% in the validation cohort (P < 0.001). 4.6 The company presented clinical effectiveness results for the PEGASUSTIMI 54 trial whole population who had ticagrelor compared with placebo (ticagrelor n7,045, placebo n7,067). In the derivation cohort, the area under the curve of the score for the primary endpoint (1-year death and non-fatal AMI) was 0.70 (95% CI 0.65-0.76 P < 0.0001) and a cut-off of 6 was identified. We externally validated our score in 913 AMI patients with a longer follow-up. inhibitor, extends to stable patients with a remote history of MI. We calculated a cut-off for the developed score and investigated its 1-year prognostic power in the derivation cohort (n = 1257). PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Tica-grelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial sought to determine whether the benefit of tica-grelor, a newer generation P2Y. We retrospectively analyzed two prospectively collected AMI cohorts.
We aimed to elaborate a risk score, based on the PEGASUS-TIMI 54 criteria, to predict mortality and non-fatal AMI in AMI patients. Acute myocardial infarction (AMI) patients are at increased risk of death and recurrent ischemic events.
0 kommentar(er)
